AGP Executive Report
Last update: 10 hours agoMedical AI policy: The FDA released a discussion paper on how to regulate generative AI-enabled medical devices, proposing a risk framework and asking for public input. HIV treatment: Gilead’s once-daily HIV pill Bixlenvo won FDA approval, using a bictegravir/lenacapavir combo with a brief loading step. Cybersecurity in healthcare: Boston Scientific said its cyberattack is still disrupting systems and has no restoration timeline; the FDA also flagged a separate catheter manufacturing issue and ordered market removal. Biotech diagnostics: BRIC-RGCB researchers unveiled a nanopore sensor aimed at early Parkinson’s and ALS biomarker detection. Regenerative medicine: Chinese teams reported injectable muscle grafts that contract and restore strength in mice, while other studies explore new ways to generate neurons and target degenerative conditions. Climate & health: A global study estimates climate change adds extra heat stress for hundreds of millions of children. Energy & industry: Canada pledged CAD 195M to Xanadu for quantum photonics manufacturing, and NIO Power delivered the first 23 battery swap stations with Science City Group. Science education & culture: London’s Science Museum ended its long BP partnership.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
